"Following disease progression with abiraterone (Zytiga), treatment with bipolar androgen therapy (BAT) or enzalutamide (Xtandi) led to a median progression-free survival (PFS) of 5.7 months (clinical or radiographic progression). A similar proportion of patients in each treatment arm had at least a 50% reduction in baseline PSA level (PSA50 response), and overall survival (OS) did not differ significantly between the groups, reported Samuel R. Denmeade, MD, of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, and colleagues.
The median time to PSA progression (PSA-PFS) with enzalutamide increased from 3.8 months after abiraterone to 10.9 months after crossover from BAT (P=0.008). The results suggested BAT might have a role in altering the adaptive process that transforms hormone-sensitive prostate cancers into CRPC, they stated in the Journal of Clinical Oncology."